Ramucirumab
| CAS No. | 947687-13-0 | Cat. No. | BCP26258 |
| Name | Ramucirumab | ||
| Synonyms | LY3009806; IMC-1121B; | ||
| Formula | C6374H9864N1692O1996S46 | M. Wt | 6369.07 |
| Description | Ramucirumab is a fully human monoclonal antibody (IgG1). Ramucirumab is a direct VEGFR2 antagonist, that binds with high affinity to the extracellular domain of VEGFR2 and block the binding of natural VEGFR ligands (VEGF-A, VEGF-C and VEGF-D). These ligands are secreted by solid tumors to promote angiogenesis (formation of new blood vessels from pre-existing ones) and enhance tumor blood supply. Binding of ramucirumab to VEGFR2 leads to inhibition of VEGF-mediated tumor angiogenesis. | ||
| Pathways | Angiogenesis/Protein Tyrosine Kinase | ||
| Targets | VEGFR | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.